Answers are grounded in this paper and cite their sources.
Research demonstrates macrophage subtype differentiation impacts pathogenesis in dermatological diseases, suggesting new therapy targets.
Macrophages (Ms) are essential innate immune cells that play a crucial role in maintaining tissue homeostasis and defending against infection. They exhibit significant heterogeneity and plasticity, enabling differentiation into various subtypes in response to distinct microenvironmental cues. Recent advances have illuminated the roles of classically activated (M1) and alternatively activated (M2) types and other specialized macrophage subpopulations in inflammatory skin diseases, wound healing, autoimmune disorders, and other dermatological conditions. Targeting key molecules or markers involved in macrophage subtype differentiation—such as STAT3, STAT6, and CD163—offers promising therapeutic opportunities for the treatment of dermatological diseases.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: